EA201592166A1 - N-(гетероарил)-сульфонамидные производные, которые могут применяться в качестве s100-ингибиторов - Google Patents
N-(гетероарил)-сульфонамидные производные, которые могут применяться в качестве s100-ингибиторовInfo
- Publication number
- EA201592166A1 EA201592166A1 EA201592166A EA201592166A EA201592166A1 EA 201592166 A1 EA201592166 A1 EA 201592166A1 EA 201592166 A EA201592166 A EA 201592166A EA 201592166 A EA201592166 A EA 201592166A EA 201592166 A1 EA201592166 A1 EA 201592166A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- heteroaril
- inhibitors
- disorders
- compound
- sulphonamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Соединение формулы (I)или его фармацевтически приемлемая соль и фармацевтическая композиция, содержащая данное соединение. Соединение представляет собой ингибитор взаимодействия между S100A9 и взаимодействующих с ним партнеров, таких как RAGE, TLR4 и EMMPRIN, и в таком качестве может использоваться в лечении таких нарушений, как рак, аутоиммунные нарушения, воспалительные нарушения и нейродегенеративные нарушения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13167680 | 2013-05-14 | ||
PCT/EP2014/059829 WO2014184234A1 (en) | 2013-05-14 | 2014-05-14 | N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201592166A1 true EA201592166A1 (ru) | 2016-05-31 |
EA028512B1 EA028512B1 (ru) | 2017-11-30 |
Family
ID=48366235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201592166A EA028512B1 (ru) | 2013-05-14 | 2014-05-14 | N-(гетероарил)сульфонамидные производные, которые могут применяться в качестве s100-ингибиторов |
Country Status (13)
Country | Link |
---|---|
US (2) | US9873687B2 (ru) |
EP (1) | EP2925743B1 (ru) |
JP (1) | JP6322280B2 (ru) |
KR (1) | KR20160006717A (ru) |
CN (1) | CN105377837B (ru) |
AU (1) | AU2014267360B2 (ru) |
BR (1) | BR112015027395A2 (ru) |
CA (1) | CA2912313A1 (ru) |
EA (1) | EA028512B1 (ru) |
ES (1) | ES2563902T3 (ru) |
HK (1) | HK1213254A1 (ru) |
MX (1) | MX360455B (ru) |
WO (1) | WO2014184234A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220378763A1 (en) * | 2019-06-28 | 2022-12-01 | Calprotect Ab | Compound for treatment of acute inflammation in the myocardium |
CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
CN112480106B (zh) * | 2020-11-17 | 2022-09-02 | 南京海纳医药科技股份有限公司 | 一种马来酸阿伐曲泊帕杂质的制备方法 |
CN115974772A (zh) * | 2023-01-05 | 2023-04-18 | 山东铂源药业股份有限公司 | 一种利用微通道反应器制备吡啶-3-磺酰氯的方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3313806A (en) | 1963-07-01 | 1967-04-11 | Sumitomo Chemical Co | Sulfanilylaminopyridazinone derivatives and method for their production |
AU6944696A (en) * | 1995-09-14 | 1997-04-01 | Shionogi & Co., Ltd. | Novel phenylacetic acid derivatives and medicinal composition containing the same |
AU2002358390A1 (en) * | 2001-12-18 | 2003-06-30 | Astrazeneca Ab | Novel compounds |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
US20060004085A1 (en) * | 2002-03-29 | 2006-01-05 | University Of Maryland , Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
JPWO2005023771A1 (ja) | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
WO2006122723A1 (en) * | 2005-05-19 | 2006-11-23 | Vaecgene Biotech Gmbh | Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections |
KR20080049767A (ko) | 2005-08-26 | 2008-06-04 | 라보라뚜와르 세로노 에스. 에이. | 피라진 유도체 및 pi3k 억제제로서의 용도 |
GB0524786D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US8470859B2 (en) | 2006-10-23 | 2013-06-25 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
MX2012002420A (es) | 2009-08-26 | 2012-06-27 | Novartis Ag | Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4. |
US20110160200A1 (en) * | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
WO2011085129A2 (en) | 2010-01-06 | 2011-07-14 | Errico Joseph P | Methods and compositions of targeted drug development |
WO2011133444A1 (en) * | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US9233946B2 (en) * | 2010-09-17 | 2016-01-12 | Kancera Ab | Sulfonamide compounds |
-
2014
- 2014-05-14 CA CA2912313A patent/CA2912313A1/en not_active Abandoned
- 2014-05-14 US US14/890,938 patent/US9873687B2/en active Active
- 2014-05-14 BR BR112015027395A patent/BR112015027395A2/pt not_active Application Discontinuation
- 2014-05-14 CN CN201480027366.6A patent/CN105377837B/zh active Active
- 2014-05-14 EP EP14723807.5A patent/EP2925743B1/en active Active
- 2014-05-14 MX MX2015015741A patent/MX360455B/es active IP Right Grant
- 2014-05-14 EA EA201592166A patent/EA028512B1/ru not_active IP Right Cessation
- 2014-05-14 AU AU2014267360A patent/AU2014267360B2/en active Active
- 2014-05-14 JP JP2016513346A patent/JP6322280B2/ja active Active
- 2014-05-14 WO PCT/EP2014/059829 patent/WO2014184234A1/en active Application Filing
- 2014-05-14 ES ES14723807.5T patent/ES2563902T3/es active Active
- 2014-05-14 KR KR1020157034181A patent/KR20160006717A/ko not_active Application Discontinuation
-
2016
- 2016-02-02 HK HK16101156.0A patent/HK1213254A1/zh unknown
-
2017
- 2017-12-08 US US15/836,036 patent/US10125125B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180155330A1 (en) | 2018-06-07 |
EP2925743B1 (en) | 2016-02-03 |
EP2925743A1 (en) | 2015-10-07 |
HK1213254A1 (zh) | 2016-06-30 |
MX2015015741A (es) | 2016-03-16 |
WO2014184234A1 (en) | 2014-11-20 |
KR20160006717A (ko) | 2016-01-19 |
CN105377837B (zh) | 2017-08-04 |
AU2014267360B2 (en) | 2018-07-05 |
US20160115158A1 (en) | 2016-04-28 |
JP2016518428A (ja) | 2016-06-23 |
MX360455B (es) | 2018-11-01 |
BR112015027395A2 (pt) | 2017-08-29 |
ES2563902T3 (es) | 2016-03-16 |
AU2014267360A1 (en) | 2015-12-17 |
JP6322280B2 (ja) | 2018-05-09 |
US10125125B2 (en) | 2018-11-13 |
US9873687B2 (en) | 2018-01-23 |
CN105377837A (zh) | 2016-03-02 |
EA028512B1 (ru) | 2017-11-30 |
CA2912313A1 (en) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091186A1 (ru) | ИНГИБИТОРЫ KRas G12C | |
EA201690734A1 (ru) | Ингибиторы бромодомена | |
EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201790649A1 (ru) | Бензилзамещенные индазолы в качестве ингибиторов bub 1 | |
EA201792229A1 (ru) | Ингибиторы бромодомена | |
EA201690753A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
EA201890239A2 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
EA201592157A1 (ru) | Низкомолекулярные ингибиторы фиброза | |
EA201690027A1 (ru) | Ингибиторы ido | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
EA201591764A1 (ru) | Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы | |
EA201591340A1 (ru) | Модулятор андрогенного рецептора и его применения | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
EA201690764A1 (ru) | Ингибитор грелин-o-ацилтрансферазы | |
EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |